Latest Industry Insights

A new pan-European network will integrate long-read sequencing into clinical practice, improving diagnosis of rare diseases and cancers.

To explore how the CGT landscape is evolving, Technology Networks spoke with Betty Woo, vice president of Cell, Gene and Advanced Therapies at Thermo Fisher Scientific.

In this interview, Asim Siddiqui, senior vice president and scientific fellow at Seer, explores the evolving role of unbiased proteomics in cancer research.

In this article, Cristiana Bercea discusses how large, automated storage solutions are helping companies to save time, unlock greater efficiency and better meet sustainability goals – without increasing risk.

In this interview, Dr. Christian Schafmeister discusses the structural advantages of Spiroligomer molecules, their ability to disrupt protein–protein interactions and their potential applications in cancer therapy and beyond.

In an interview with Arthur Stril, chief business officer and interim CFO at Cellectis, we explore how gene editing and innovative manufacturing strategies are overcoming the key limitations of autologous CAR T-cell therapy.

UK Biocentre is adopting Azenta’s BioArc™ Ultra™, an automated -80°C storage system, to enhance biobanking efficiency and sustainability. With high-density storage and precise temperature control, it safeguards valuable samples.

In this opinion piece, Philipp Koellinger explores the changes required to level the playing field and accelerate both scientific and technological progress.

Vivek Vishnudas discusses the unique advantages of E2-based TPD and its potential to revolutionize treatment for challenging diseases.

Cancer Research Horizons and Diamond Light Source aim to strengthen their partnership, combining their expertise and resources to bring new cancer treatments to patients.